SCHEMBL10108282

SCHEMBL10108282

Cn1c(S(C)(=O)=O)nc([N+](=O)[O-])c1CBr

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
HTT P42858 2/20 0.45
MITF O75030 1/20 0.45
ALPL P05186 1/20 0.45
POLB P06746 1/20 0.45
APEX1 P27695 1/20 0.45
APOBEC3A P31941 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
KMT2A Q03164 3/20 0.35
LMNA P02545 2/20 0.35
BLM P54132 1/20 0.35
GAA P10253 1/20 0.31
ALDH1A1 P00352 2/20 0.30
JAK2 O60674 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C19 P33261 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102725 0.77 GAA (0.34) MAPTHTTPOLBSMN1; SMN2KMT2A
SCHEMBL867642 0.77 KMT2A (0.41) MAPTHTTPOLBSMN1; SMN2KMT2A
SCHEMBL10108277 0.77 MAPT (0.50) MAPTHTTMITFALPLPOLB
SCHEMBL10102761 0.76 KDM4E (0.39) MAPTHTTPOLBSMN1; SMN2KMT2A
SCHEMBL10102781 0.74 MAPT (0.39) MAPTHTTPOLBSMN1; SMN2KMT2A
SCHEMBL867643 0.73 GAA (0.35) MAPTHTTPOLBSMN1; SMN2KMT2A
SCHEMBL10102721 0.73 MAPT (0.32) MAPTGAAALDH1A1
SCHEMBL10102756 0.73 MAPT (0.32) MAPTGAAALDH1A1
SCHEMBL10108153 0.72 MAPT (0.32) MAPTGAA
SCHEMBL10108280 0.72 MAPT (0.32) MAPTHTTPOLBKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-01-07 US disclosed
US-9073916-B2 Prodrug forms of kinase inhibitors and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-07-07 US disclosed
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K MAPT 3315/4885HTT 3450/4885MITF 3770/4885
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K MAPT 3259/4885HTT 3186/4885MITF 3653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.